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Abstract
Background: The amino-acid balance in cancer patients often differs from that in healthy individuals, because of
metabolic changes. This study investigated the use of plasma amino-acid profiles as a novel marker for screening
non-small-cell lung cancer (NSCLC) patients.
Methods: The amino-acid concentrations in venous blood samples from pre-treatment NSCLC patients (n = 141),
and age-matched, gender-matched, and smoking status-matched controls (n = 423), were measured using liquid
chromatography and mass spectrometry. The resultant study data set was subjected to multiple logistic regression
analysis to identify amino acids related with NSCLC and construct the criteria for discriminating NSCLC patients
from controls. A test data set derived from 162 patients and 3,917 controls was used to validate the stability of the
constructed criteria.
Results: The plasma amino-acid profiles significantly differed between the NSCLC patients and the controls. The
obtained model (including alanine, valine, isoleucine, histidine, tryptophan and ornithine concentrations) performed
well, with an area under the curve of the receiver-operator characteristic curve (ROC_AUC) of >0.8, and allowed
NSCLC patients and controls to be discriminated regardless of disease stage or histological type.
Conclusions: This study shows that plasma amino acid profiling will be a potential screening tool for NSCLC.
Background
Recently, computer-aided systems for data mining, for
example by multivariate analysis, are now readily avail-
able and have shown promising results when applied to
metabolic profiling for diagnostic purposes [1,2]. Cur-
rently, several applications of metabolome analysis based
on machine learning for human cancer diagnosis using
peripheral blood or urine were demonstrated [3-10].
Among metabolites, the amino-acid balance in
patients with various diseases often differs from that
maintained in healthy individuals, as a result of meta-
bolic changes. Amino acids are considered to be central
compounds within metabolic networks. The blood
serves as the medium linking the metabolic processes in
the different organs of the human body. Human amino-
acid metabolism in the blood has been monitored clini-
cally for >30 years. Fischer’s ratio, which is defined as
the balance between branched-chain amino acids
(BCAAs) and aromatic amino acids, has been used as an
indicator of both the progression of liver fibrosis and
the effectiveness of drug treatment [11]. Specific
abnormalities in amino-acid concentrations, as assessed
using multivariate analysis, have also been reported in
animal models of diabetes, in human liver fibrosis and
in other pathologies [12-14].
The metabolism in cancer cells is known to be signifi-
cantly altered compared with that in normal cells, and
these changes are also reflected in the plasma amino-
acid profiles of patients with various types of cancer.
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amino acids (GAAs) and a significant increase in free
tryptophan have been reported in lung cancer patients
[15]. Kubota et al. used plasma amino-acid profiles to
discriminate between patients with breast cancer, gastro-
intestinal cancer, and head and neck cancers, and
healthy controls [16]. Therefore, detecting metabolic
changes from amino-acid profiles could potentially be
useful in cancer diagnosis.
Post-genomic technologies also offer possibilities for
exploiting amino-acid profiling. Recently, novel methods
for analyzing amino acids have been established using
high-performance liquid chromatography (HPLC)-electro-
spray ionization (ESI)-mass spectrometry (MS) [17-19].
This will help to make amino-acid measurements easier
and reduce both the time and the cost of analysis.
Therefore, one potentially useful metabolomics tool is
the “AminoIndex”, which could be a simple and versatile
method for monitoring various pathological conditions
[12]. Here we investigated the possibility of “AminoIn-
dex” as a novel diagnostic method for the screening of
non-small-cell lung cancer (NSCLC).
Methods
All of the patients in the study had been diagnosed histo-
logically with NSCLC at the Osaka Medical Centre for
Cancer and Cardiovascular Diseases, Japan, between Jan-
uary 2006 and October 2008. While hospitalized, their
informed consent for inclusion was obtained. Data from
the first 141 patients enrolled between January 2006 and
September 2007 were used as the study data set. A
further 4,340 subjects without apparent cancers, who
were undergoing comprehensive medical examinations at
the Mitsui Memorial Hospital, Japan, in 2008, were
recruited as control subjects. Of these, 423 were age-
matched, gender-matched, and smoking status-matched
w i t ht h ep a t i e n t si nt h es t u d yd a t as e tg r o u p .D a t af r o m
the remaining patients and control subjects were used as
the test data set. Data from an additional 15 SCLC
patients, who were hospitalized at the Osaka Medical
Centre for Cancer and Cardiovascular Diseases, Japan,
between January 2006 and October 2008, were also used.
Blood samples were collected from the controls and the
NSCLC patients before any medical treatment. The study
was conducted in accordance with the Declaration of
Helsinki, and the protocol was approved by the ethics
committees of the Osaka Medical Centre for Cancer and
Cardiovascular Diseases and Mitsui Memorial Hospital.
All subjects gave their informed consent for inclusion
before they participated in the study.
Analytical methods
Blood samples (5 ml) were collected from forearm
veins, after overnight fasting, in tubes containing
ethylenediaminetetraacetic acid (EDTA; Termo, Tokyo,
Japan), and were immediately placed on ice. Plasma was
prepared by centrifugation at 3,000 rpm and 4°C for
15 min, and then stored at -80°C until analysis. After
plasma collection, all samples were stored and processed
at the Life Science Institute of Ajinomoto Co., Inc.
(Kawasaki, Japan). To reduce any bias introduced prior
to analysis, samples were analyzed in random order. The
plasma samples were deproteinized using acetonitrile at
a final concentration of 80% before measurement. The
amino-acid concentrations in the plasma were measured
by HPLC-ESI-MS, followed by precolumn derivatization
[17-19]. The analytical methods were described in detail
previously [17]. The concentrations of amino acids in
the plasma were expressed as μM.
Statistical analysis of plasma amino-acid profile
The mean amino-acid concentrations ± standard devia-
tions (SDs) were calculated. Differences between the
plasma amino-acid concentrations in NSCLC patients
and controls were assessed using the Mann-Whitney U-
test and receiver-operator characteristic (ROC) curve.
The area under the curve (AUC) for each ROC curve
(the ROC_AUC) was calculated for each amino acid.
Principal component analysis (PCA) was also used to
assess differences in the plasma amino-acid profile
between the controls and the NSCLC patients, with lin-
ear combinations of all of the amino acids included as
explanatory variables. In PCA analysis the plasma
amino-acid concentrations were transformed using the
following equation:
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where zi,j was transformed concentration of of the i-th
sample of the j-th amino acid, xi,j was concentration of
the i-th sample of the j-th amino acid, n was sample
size, and X j was the average concentration of j-th
amino acid.
Machine learning and validation
First, an unconditional multiple logistic regression analy-
sis with variable selection was used to construct a criter-
ion for distinguishing NSCLC patients from controls
using the study data set with the raw plasma concentra-
t i o n so f2 1a m i n oa c i d sa se x p l a n a t o r yv a r i a b l e s .T h e
candidate variables of most appropriate logistic regres-
sion model, which had the minimum Akaike’si n f o r m a -
tion criterion (AIC) value, were selected from among all
of the possible combinations in which the number
of variables was below seven. A leave-one-out cross-vali-
dation (LOOCV) was performed to correct potential
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sample was omitted from the study data set, and the
logistic regression model was calculated for the remain-
ing samples, to estimate coefficients for each amino
acid. The logistic regression function values for the left-
out sample were calculated based on the model. This
process was repeated until every sample in the study
data set had been left out once, and the function values
generated were then used for AIC calculation. Finally, a
case-control study was utilized for our study, and so a
conditional logistic regression analysis, conditioned on
the matching factors (i.e., gender, age, and smoking sta-
tus), was performed in order to evaluate the association
between the combination of amino acids obtained above
and NSCLC. The discriminant score, which was defined
as a logit of the conditional logistic regression function
value, was constructed as a criterion. The degree of dis-
criminancy of this score between NSCLC patients and
controls was evaluated through the ROC curve. A dis-
tinct test data set, which had not been used in the
model generation, was also used to confirm the stability
of the obtained model, and to calculate the ROC_AUC
values for the discriminant scores.
Subgroup analysis
To assess the effects of cancer stage and histological
type, both the study data set and the test data set was
stratified according to the analysis parameters. To assess
the effects of cancer stage and histological type on the
discriminant scores of NSCLC patients, a subgroup ana-
lysis was performed using the ROC curve, in each data
set. A two-sided P value of less than 0.05 was consid-
ered to indicate statistical significance.
Software
All statistical analyses were performed using MATLAB
(The Mathworks, Natick, MA), LogXact (Cytel, Cam-
bridge, MA), and GraphPad Prism (GraphPad Software,
La Jolla, CA).
Results
Characteristics of patients and control subjects
The study data set comprised 141 patients with NSCLC,
and 423 age-matched, gender-matched, and smoking
status-matched control subjects, whereas there were 162
patients and 3,917 controls in the test data set; a further
15 SCLC patients were also included (Table 1). Among
the patients, 28% and 36% were non-smokers in the
study and test data sets, respectively, whereas almost
50% of the control subjects were non-smokers (Table 1).
There were no significant differences in body mass
index (BMI) between the patients and the control sub-
jects (Table 1). In both the study and test data sets
~50% of the patients were categorized as having stage I
disease, ~5% as stage II, ~25% as stage III and ~20% as
s t a g eI V( T a b l e1 ) .T h eE a s t e r nC o o p e r a t i v eO n c o l o g y
Group performance status (ECOG) score of most
patients was 0 or 1; hence, the majority of the patients
were asymptomatic or symptomatic but completely
ambulatory (Table 1). The histological type was adeno-
carcinoma in almost 75% of the patients and squamous
cell carcinoma in almost 25%, the other types present
included large-cell carcinoma, adenosquamous carci-
noma, pleomorphic carcinoma and mucoepidermoid
carcinoma (Table 1).
Changes in amino-acid concentrations in NSCLC patients
In the study data set, the plasma concentration of His
was significantly lower, and those of Ser, Pro, Gly, Ala,
Met, Ile, Leu, Tyr, Phe, Orn, and Lys were significantly
higher, in NSCLC patients than in controls (Table 2).
Amino acids in the human body undergo interdepen-
dent regulation; comparing single amino-acid concentra-
tions between controls and patients might thus be
insufficient to elucidate any changes in plasma amino-
acid profiles associated with cancer development.
Changes in the balance of the plasma amino acids in
the study data set were therefore investigated using
principal component analysis (PCA) in the current
study. Five PCs with eigenvalues >1 were identified
(Table 3). To evaluate their performance, the Mann-
Whitney U-test was used to compare each PC score
between the controls and NSCLC patients. Three of the
PCs showed significant p values (< 0.001): PC1, PC3,
and PC5 (Table 3). The contributing amino acids for
the PCs that had a variance of >0.05 were then
extracted; the results identified Ala, Val, Met, Ile, Leu,
Tyr, Phe, Trp, and Lys as contributing factors for PC1,
Cit, His, Trp, Orn, and Arg as contributing factors for
PC3, and Ser, Gly, Cit, His, and Arg as contributing fac-
tors for PC5 (Table 3). As a result, fifteen amino acids
(Ser, Gly, Ala, Cit, Val, Met, Ile, Leu, Tyr, Phe, His, Trp,
Orn, Lys, and Arg) were identified as whose profile in
plasma were associated with NSCLC (Table 3).
Classifier for discriminating NSCLC patients
T h er e s u l t sd e s c r i b e ds of a rs u g g e s t e dt h a ti ts h o u l db e
possible to improve the discrimination between cancer
patients and normal controls by deriving multivariate
functions, using the raw plasma amino-acid concentra-
tions as explanatory variables, which would summarize
the changes in metabolic status. Multiple logistic regres-
sion analyses by unconditional and conditional likeli-
hood methods were therefore performed with variable
selection and LOOCV cross-validation, using the study
data set (as described in the Methods). The resulting
conditional logistic regression model included six amino
acids: Ala (p = 0.007), Val (p < 0.001), Ile (p < 0.001),
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T h ea r e au n d e rt h ec u r v e( A U C )o ft h eR O Cf o r
the discriminant score was 0.817 in the study data set
(Figure 1).
Furthermore, to verify the robustness of the resulting
m o d e l ,aR O Cc u r v ew a sg e n e r a t e du s i n gt h es p l i tt e s t
data set, which had not been used to construct the
model. A ROC_AUC of the ROC for the discriminant
score was 0.812 in the test data set (Figure 1), again
demonstrating that the obtained model performed well.
Subgroup analysis of the discriminant scores
From the point of view of cancer screening, attention
might be paid to whether or not the obtained model
also provides sufficient discriminating power to extract
effectively patients with early-stage cancer and for all
histological types. Thus, to investigate the consistency of
the results based on the discriminant scores among dif-
ferent subpopulations defined by cancer stage and histo-
logical type, a subgroup analysis was performed using
both study data set and the test data set. The discrimi-
nant scores of the SCLC patients were also calculated to
verify whether the obtained model could discriminate
them from the controls.
Interestingly, it was suggested that the model could
discriminate lung cancer patients regardless of cancer
stage or histological type. Using the discriminant scores,
the ROC_AUCs were 0.796 (study data set) and 0.817
(test data set) for stage I patients, 0.906 (study data set)
and 0.801 (test data set) for stage II patients, 0.823
(study data set) and 0.843 (test data set) for stage III
patients, and 0.836 (study data set) and 0.713 (test data
s e t )f o rs t a g e sI Vp a t i e n t s( F i g u r e2 A ,B ) .T h em o d e l
would thus be expected to be effective in detecting
early, as well as advanced, cancers. We also demon-
strated that the model could detect both adenocarcino-
mas and other histological types of cancer equally well:
the ROC_AUCs were 0.795 (study data set) and 0.796
(test data set) for adenocarcinoma, and 0.860 (study
data set) and 0.892 (test data set) for squamous cell car-
cinoma (Figure 2C, D). Furthermore, the distribution of
the discriminant scores for SCLC patients was similar to
that for NSCLC patients, with a ROC_AUC of 0.877
(Figure 2D).
Table 1 Characteristics of study participants
Study data set Test data set SCLC
Controls Patients Controls Patients patients
Number Total 423 141 3917 162 15
(Male, Female, Unknown) (279,144) (93,48) (2363,1554) (103,55,4) (15,0)
Age, y Mean (SD) 61.1(8.7) 62.7(9.2) 52.6(10.8) 65.7(10.4)* 66.8(8.1)*
Range 32~82 34~83 23~88 34~83 50~76
BMI Mean (SD) 23.0(3.1) 22.6(2.8) 22.7(3.2) 22.8(3.1) 22.7(3.5)
Range 16.5~36.4 15.4~29.8 14.0~41.3 15.8~35.1 17.7~30.7
Smoking status Never 126 42 2020 55 0
Ex 45 15 1304 25 5
Current 237 79 554 81 10
Unknown 15 5 39 1 0
Performance 0 95 129 6
14 1 3 1 5
>1 2 0 2
Unknown 3 2 2
Stage** I 69 93 6
II 8 16 0
III 39 30 6
IV 25 12 3
Unknown 0 11 0
Histology Adenocarcinoma 100 123
Squamous cell carcinoma 36 33
Others 4 5
Unknown 1 1
* Significant at p < 0.001 in t-test
** In principle, stage indicates pathological stage (p-stage). In some advanced stage (III and IV) patients who had not undergone pathological examinations,
clinical stage (c-stage) is indicated instead.
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Lung cancer has been the leading cause of cancer death
since 1998 and >60,000 patients have died since 2005 in
Japan. The 5-year survival rate for patients undergoing
surgery is only 61%, and an accurate screening method
for lung cancer would be an important advance [20]. In
Japan, chest X-rays and sputum cytology are used for
screening lung cancer. Although chest X-rays are useful
for detecting peripheral lung cancer, two-thirds of
patients diagnosed in this way have associated metas-
t a s e s ,a n dt h i sm e t h o di sn o tsufficient to detect the
early stages of the disease [21]. In addition, highly
skilled staffs are required to achieve sufficient accuracy.
Sputum cytology might be useful for detecting upper
respiratory-tract carcinoma, but this method has been
reported to be inadequate for detecting peripheral lung
cancer and lung cancer in asymptomatic non-smokers
[21]. Recently, low-dose helical computed tomography
(CT) was reported to be capable of detecting small,
early lung cancers in high-risk populations; however, it
is not known whether using this method would affect
the mortality rate due to lung cancer or whether it
would be cost-effective [22].
In comparison to those methods, the “AminoIndex”
would be easier to use, as it involves a relatively simple
plasma assay, imposes a lower physical burden on
patients and does not require advanced technical skills
to perform [12]. The current study demonstrated that
plasma amino acid profiles were associated with
NSCLC. The ROC_AUCs were 0.817 for the study data
Table 2 Plasma amino-acid concentration
Plasma concentration, μM
Amino acid Patients (n = 141) Controls (n = 423) p value
Mean SD Mean SD
Thr 115.6 28.6 115.9 25.4 0.92
Ser 117.1 19.9 111.4 17.9 0.003
Asn 45.1 8.2 44.8 7.2 0.72
Glu 46.7 19.4 45.7 19.5 0.60
Gln 580.5 93.3 587.9 83.5 0.40
Pro 168.0 43.6 150.9 41.4 < 0.001
Gly 263.6 63.2 237.0 57.3 0.000
Ala 422.3 97.4 383.7 88.9 0.000
Cit 34.4 10.6 33.2 8.3 0.20
ABA 24.2 8.4 23.2 6.9 0.20
Val 244.8 47.5 239.8 46.1 0.28
Met 29.4 6.1 28.0 5.2 0.013
Ile 84.3 22.1 69.7 17.5 < 0.001
Leu 131.8 34.3 122.4 27.6 0.003
Tyr 80.7 15.6 75.8 15.5 0.001
Phe 67.9 12.2 63.9 11.2 0.001
His 77.3 15.0 80.8 10.7 0.010
Trp 59.3 12.0 59.8 10.9 0.67
Orn 67.6 19.7 54.4 12.3 < 0.001
Lys 211.5 36.2 200.3 34.1 0.001
Arg 101.3 21.6 98.1 17.8 0.12
Study data set was used.
Table 3 PCA of plasma amino-acid profile of study
data set
PC1 PC2 PC3 PC4 PC5
Thr -0.204 0.266 -0.187 0.096 -0.100
Ser -0.123 0.400 -0.016 -0.240 -0.369
Asn -0.211 0.296 -0.269 -0.040 -0.031
Glu -0.146 -0.374 0.089 0.072 -0.132
Gln -0.128 0.290 -0.032 0.078 0.169
Pro -0.211 -0.064 0.153 0.490 -0.214
Gly 0.021 0.384 0.154 0.073 -0.435
Ala -0.240 -0.057 -0.136 0.295 -0.220
Cit -0.138 0.214 0.379 0.141 0.394
ABA -0.177 -0.002 -0.033 -0.396 -0.212
Val -0.287 -0.190 0.033 -0.235 -0.034
Met -0.309 0.095 -0.101 0.052 0.060
Ile -0.294 -0.226 0.205 -0.127 -0.118
Leu -0.304 -0.228 0.054 -0.258 -0.029
Tyr -0.269 -0.089 -0.005 0.353 -0.086
Phe -0.240 -0.117 -0.066 0.005 0.163
His -0.188 0.088 -0.484 -0.010 0.256
Trp -0.231 -0.109 -0.328 0.090 0.112
Orn -0.219 0.104 0.427 0.041 -0.053
Lys -0.231 0.075 0.153 -0.367 0.107
Arg -0.176 0.225 0.256 0.020 0.421
Eigenvalue 5.897 2.346 1.369 1.214 1.167
p value < 0.001 0.99 < 0.001 0.23 < 0.001
PCs that had eigenvalues of >1 are indicated. Bold numbers indicate the
amino acids of those PCs extracted that had a variance of >0.05. The Mann-
Whitney U-test p values for comparisons of each PC score between the
controls and NSCLC patients are shown.
Figure 1 ROC curves for discriminant scores for the
discrimination of NSCLC.
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conditioned on the matching factors (Figure 1).
Okamoto et al. recently reported that plasma amino-
acid profiles might be used to screen colorectal and
breast cancer [23]. Despite the smaller sample size, they
reported ROC_AUCs of 0.860 (with study data) and
0.910 (with test data) for colorectal cancer patients, and
0.906 (with study data) and 0.865 (with test data) for
breast cancer patients [23]. Our current study achieved
similar discrimination power using data set with a larger
sample size under controlling for potential confounders,
thereby demonstrating the robustness of the model.
Many reports have shown that the metabolism,
including that of amino acids, is notably altered in can-
cer cells [4,24-26], and that the plasma amino-acid
profiles are also changed [15,16,27-30]. Cascino et al.
described significant increases in levels of Trp, Glu and
Orn in lung cancer patients [15]. Proenza and colleagues
also reported an increased level of Orn in patients with
lung cancer [29]. Naini et al. reported reduced levels of
plasma Arg in lung cancer patients [31].
Changes in the amino-acid balance and an increase in
gluconeogenesis have been well documented, especially
in cachexic patients with advanced cancer [32,33]. In
the current study, the obtained model identified patients
at all stages of lung cancer and without cachexia equally
well, suggesting that the method did not rely on detect-
ing metabolic abnormalities associated with malnutri-
tion, which might be present in advanced cancer
patients (Figure 2A, B). Hirayama et al. reported no
Figure 2 ROC curves for discriminant scores subgrouped by cancer stage and histological type. A. ROC curves for cancer stage of study
data set. B. ROC curves for cancer stage of test data set. C. ROC curves for histological type of study data set. D. ROC curves for histological type
of test data set (including SCLC patients).
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including several amino acids, and the patients’ tumour
stage [24]. And it was also reported that amino acids
were frequently identified compounds among whole
metabolites in blood in relation to cancer [3,8]. The
metabolism of specific amino acids is known to be asso-
ciated with specific organs, such as muscle, liver or kid-
ney, changes in the levels of amino acids are affected by
their metabolism in, and excretion from, multiple organs
of the body. Although it remains unclear how the meta-
bolic changes occurring in tumour cells affect the sys-
temic, plasma amino-acid profile, these results show
that the metabolic changes caused by cancer develop-
ment are at least partially responsible for the changes in
plasma amino-acid profile seen even in lung cancer
patients with early stage cancer. So, profiling the plasma
free amino acids is similar to monitoring metabolic net-
works in multiple organs and it might better allow us to
detect particular conditions in specific organs.
Since this study was designed as a case-control study,
the obtained model could not be directly applied to
further observation or prediction even though the
robustness of the model was preliminarily demonstrated.
Therefore model construction and validation using
cohort with larger samples will be necessary to clarify
its utility. Nonetheless, we believe that this screening
technique could be a straightforward diagnostic method
for the management of lung cancer.
Conclusions
The current study demonstrated that the plasma amino-
acid profile of NSCLC patients differed from that of
healthy subjects. And we showed that the multivariate
classifier might be effective for discriminating lung can-
cer patients. Although further prospective validation will
be necessary in the future, this method might be an
effective and convenient screening tool for lung cancer
patients.
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